Growth is fuelled by rising disease burden, ageing populations, and earlier diagnosis.

The global congestive heart failure (CHF) treatment market across the seven major markets (7MM) was valued at $9b in 2025 and is projected to rise at a compound annual growth rate (CAGR) of 8% between 2026 and 2036, according to DelveInsight Business Research. The market is also expected to benefit from the potential introduction of new therapies, including omecamtiv mecarbil (Cytokinetics), ziltivekimab (NN6018; Novo Nordisk), CardiALLO Cell Therapy (BioCardia), and umiposgene parvec (Bayer). The 7MM had an estimated 21.1 million diagnosed prevalent heart failure cases in 2025. Several companies are developing new CHF therapies, including Cytokinetics, Novo Nordisk, BioCardia, Cardurion Pharmaceuticals, Bayer, AstraZeneca, Boehringer Ingelheim, Mesoblast, and AskBio. Key investigational treatments include omecamtiv mecarbil, ziltivekimab, CardiALLO Cell Therapy, CardiAMP Cell Therapy, CRD-740, umiposgene parvec, AZD5462, vicadrostat (BI 690517) combined with empagliflozin, rexlemestrocel-L, and AB-1002 gene therapy.